Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2014 09/16/2014 09/17/2014 09/18/2014 09/19/2014 Date
38.84(c) 39.5(c) 41.2(c) 41.88(c) 42.28(c) Last
3 561 274 1 598 790 3 160 691 2 650 626 2 681 058 Volume
-5.93% +1.70% +4.30% +1.65% +0.96% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer.The company operates in two segments: Drug Discovery & Development and... 
Surperformance© rating of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More about the company
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 180 M
EBIT 2014 -73,4 M
Net income 2014 -87,0 M
Finance 2014 21,5 M
Yield 2014 -
Sales 2015 163 M
EBIT 2015 -108 M
Net income 2015 -135 M
Finance 2015 213 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 27,6x
EV / Sales 2015 29,2x
Capitalization 4 978 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
4d ago ISIS PHARMACEUTICALS : Findings from Isis Pharmaceuticals, Inc. Reveals New Find..
09/03 ISIS PHARMACEUTICALS : to Present at the Morgan Stanley Global Healthcare Confer..
09/02 ISIS PHARMACEUTICALS : ATL1103 Phase II Trial - Successful Efficacy Results
09/02 ISIS PHARMACEUTICALS : Drugs from Isis' Lipid Franchise Highlighted at European ..
08/29 ISIS PHARMACEUTICALS : ISIS) Jumps 5.21% on August 25
08/28 ISIS PHARMACEUTICALS : Assigned Patent
08/28 ISIS PHARMACEUTICALS : Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients wi..
08/27 ISIS PHARMACEUTICALS : ISIS) Jumps 10.77% on August 26
08/21 ISIS PHARMACEUTICALS : Other Events (form 8-K)
08/15 ISIS PHARMACEUTICALS : Earns $2M from the Advancement of ISIS-SMN Rx in Children..
08/14 ISIS PHARMACEUTICALS : Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Ph..
08/06 ISIS PHARMACEUTICALS : Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Sp..
More news
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
08/14A resistance as obstacle
More Strategies
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
ISIS Pharmaceuticals, Inc. : Income Statement Evolution
More Financials
EPS Revisions
ISIS Pharmaceuticals, Inc. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF